These were mainly patients with SCN1A-related epilepsy (7/15), who have benefited from the introduction of first-line and add-on therapy for Dravet syndrome and/or halting carbamazepine for focal seizures. This evidence concerns the gene SCN1A and encephalopathy, progressive, early-onset, with brain edema and/or leukoencephalopathy.